Clinical Pearls on Lipid Management
A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.
Read More
Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy
Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.
The Role of Lipoprotein A in Lipid Lowering
Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.
Long-term efficacy and safety of PCSK9 inhibitors
Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.
Starting Combination Therapy Early
The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.
Nonstatin Lipid-Lowering Agents
Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.
Statin Intolerance
Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.
Disparities in Managing Patients
Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.
LDL Cholesterol as a Performance Measure
The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.
Reasons for Not Reaching Thresholds
The reasons many patients do not reach LDL-cholesterol thresholds.
Real-World Outcomes Data on Failure to Achieve LDL-C Thresholds
Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.
Real-World Data on Achieving LDL Thresholds
Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.
New Guidance in Lowering LDL-C
A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.
LDL-C and Cardiovascular Disease Risk
Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.
